HTG Hosts Scientific Webinar on Customer Integration of the HTG Transcriptome Panel in Preclinical and Clinical Programs
On June 23, 2022 HTG hosted a scientific webinar titled “Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research”.
This webinar featured Peter Ansell, Ph.D., Scientific Director and Research Fellow, Precision Medicine Oncology at AbbVie. Dr. Ansell discussed how his team at AbbVie has overcome many challenges they have previously faced using FFPE clinical samples by integrating HTG’s innovative HTG Transcriptome Panel (HTP) into their biomarker strategies.
Dr. Ansell has a long standing history of interest in the field of oncology and precision medicine. Dr. Ansell’s PhD research at University of Missouri focused on the regulation of gene expression by estrogen receptors. He determined estrogen receptors could regulate the activity of Nrf2, a transcription factor that regulates expression of genes involved in protecting cells from oxidative stress (Mol Cell Endocrinol 2005, Endocrinology 2004). As a postdoctoral researcher at Harvard Medical School, he moved on to investigate gene expression, cellular differentiation and proliferation of pituitary tumors. With more than 15 years of industry experience he is leading a team which designs and implements impactful precision medicine strategies across much of AbbVie’s solid tumor pipeline.
The presentation was facilitated by Marian Navratil, Ph.D., Senior Vice President of Research and Development at HTG, who highlighted the design and performance of the HTP based on HTG’s proprietary HTG EdgeSeq technology.
The key learning objectives of the talk included:
- Overview of advances in RNA-based gene expression profiling
- Introduction to ultra-efficient gene expression profiling (GEP) technology and its importance in maximizing reliable information while conserving precious samples
- Real-world application of the HTP, such as for clinical and preclinical oncology research
- Discussion about the benefits of novel profiling technologies compared to traditional methods